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Abstract
Background: TAZ is a downstream agent of Hippo signal pathway. β-catenin is a cell adhesion molecule associated
with the invasion and metastasis of carcinomas as well as a critical component of Wnt pathway. TAZ and β-catenin
have long been thought to play a vital role in tumour development and progression. This study aimed to detect
expression of TAZ and β-catenin in adenocarcinoma of the esophagogastric junction (AEG) and explore their
clinicopathological significance.
Methods: The expression of TAZ and β-catenin were detected by immunohistochemistry of 135 AEG samples, and
analyzed with complete clinicopathological features. Overall survival rates were also calculated using the Kaplan-Meier
method. Cox proportional hazard model was performed to assess the prognostic values. 37 normal mucosa and 41
dysplasia samples of esophagogastric junction (EGJ) were studied comparably.
Results: TAZ protein showed a strictly nuclear staining pattern in AEG and dysplasia with IHC. Expression of TAZ was
higher in dysplasia and AEG compared with normal mucosa (P<0.001, 0.008). The positive expression rate of nuclear
β-catenin was significantly higher in carcinoma and dysplasia than that in normal mucosa (P<0.001, =0.046). Abnormal
expression rate of membranous β-catenin in AEG was significantly higher than that in normal mucosa tissues and
dysplasia (P=0.001, 0.002). In AEG, over expression of TAZ was directly correlated with abnormal nuclear β-catenin
expression (r=0.298, P<0.001) and membranous β-catenin (r=0.202, P=0.019). Patients with abnormal TAZ or
β-catenin expression of AEG exhibited a shorter overall survival (OS) and lower overall survival rate than those with
normal TAZ or β-catenin expression (P<0.05). In addition, patients with abnormal expression of both TAZ and
β-catenin exhibited worst overall survival. In multivariate survival analysis, abnormal expression of TAZ, TAZ & β-catenin
(nuclear and membranous) and tumour differentiation were found to be independent prognostic factors related to OS
of AEG patients.
Conclusions: Over expression of TAZ was associated with abnormal expression of β-catenin, which is correlated with
poor prognosis of patients with AEG. Abnormal expression of TAZ and TAZ & β-catenin (nuclear and membranous) are
independent prognostic factors, so targeting TAZ and β-catenin could prove to be a promising therapeutic strategy for
the treatment of AEG.
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Adenocarcinoma of the esophagogastric junction (AEG)
is defined as carcinoma that crosses the esophagogastric
junction (EGJ) line, irrespective of where the tumour
epicenter is located, including both distal esophageal and
proximal gastric carcinomas [1]. In recent decades, AEG
has gradually become a research hotspot for its rising in-
cidence and obscure causes [2,3]. The recognition of
AEG is not unanimous for the underlying mechanisms
are poorly understood. There are still many controver-
sies in its definition, classification, diagnosis and treat-
ment. Some scientists distinguished patients with EGJ
tumours from those with gastric cancer [4], but some
treated them as esophageal cancer [5] or gastric tumours
[6]. Therefore, this study explores the features of AEG to
provide some evidence for clinical diagnosis and
treatment.
The transcriptional coactivator with PDZ-binding motif
(TAZ), also called WWTR1 (WW-domain containing
transcriptional regulator 1), was first reported as a 14-3-3
binding protein [7] which is very similar to Yes-associated
protein (YAP). It is one of the downstream agents of
Hippo pathway which plays an important role in main-
taining organ size and the regulation of cell proliferation
and apoptosis [8,9]. The core components of Hippo path-
way are mammalian STE20-like protein kinase 1/2 [10],
large tumour suppressor 1/2 [11] and their adaptor pro-
teins: Salvador homologue 1 [12] and MOB kinase activa-
tor respectively. That is a kinase cassette and finally leads
to the phosphorylation of TAZ and YAP. Phosphorylation
of YAP and TAZ loses their biological activities and stimu-
lates their ubiquitin-mediated proteolysis [13]. Conse-
quently, TAZ losses the ability of interacting with a variety
of transcription factors to regulate cell growth differenti-
ation and apoptosis, including Runx2, PPAR, TBX5,
TEADs, TTF-1, and PAX3 [14-19].
β-catenin was originally identified as a membrane
component of the cadherin-mediated cell-cell adhesion
system and it is now widely recognized as a critical
element of the Wnt signal pathway [20]. In the absence
of Wnt signals, β-catenin is located at the plasma mem-
brane, linked to E-cadherin, and functions in cell–cell
adhesion. Excess cytoplasmic β-catenin is sequestered in
a protein complex comprised of glycogen synthase kin-
ase 3β (GSK-3β), adenomatous polyposis coli (APC) and
AXIN1 or AXIN2. APC tumour suppressor gene prod-
uct regulates the level of β-catenin protein by cooperat-
ing with GSK-3β via phosphorylation of serine/threonine
residues coded on exon 3 of the β-catenin gene [21,22].
This phosphorylation is followed by degradation of β-
catenin through the ubiquitin-proteasome pathway [23].
Activated Wnt signalling inhibits the phosphorylation of
β-catenin, thereby preventing its degradation. The im-
paired β-catenin degradation leads to an increase in
cytoplasmic β-catenin and its translocation to the nu-
cleus. Nuclear β-catenin forms heterodimers with mem-
bers of the TCF family of transcription factors and
activates genes containing TCP-binding sites [24]. In
some human cancers, mutation of either the APC gene
or the β-catenin gene itself leads to the accumulation of
β-catenin within the cancer cells [21,25]. Nuclear β-
catenin is significantly associated with the invasion and
metastasis of human cancers, such as carcinomas of
esophagus, stomach, colon and melanomas [26,27].
The relationship between β-catenin and TAZ remains
controversial. Some scholars believe that in the cyto-
plasm, the coactivator TAZ inhibits the CK1-mediated
phosphorylation of Dvl2 by competing with Casein
Kinase1 for combining with Dvl2, thereby inhibiting
Wnt/β-catenin signalling and promoting the degradation
of β-catenin [28]. Inhibiting the expression of TAZ in-
creases the levels of β-catenin and downstream effectors
of Wnt pathway. But some are arguing that in the absence
of Wnt activity, the components of the β-catenin destruc-
tion complex–APC, Axin, and GSK3–are also required to
keep TAZ at low levels. TAZ degradation depends on
phosphorylated β-catenin that bridges TAZ to its ubiquitin
ligase β-TrCP. Upon Wnt signal, escape of β-catenin from
the destruction complex impairs TAZ degradation and
leads to concomitant accumulation of β-catenin and TAZ
[29]. The activation of TAZ involves in Wnt signal path-
way and mediates important biological effects [30]. The
activated hippo pathway can reduce stability and tran-
scriptional activity in nuclear of β-catenin by phosphoryl-
ation of YAP and TAZ [31].
Although β-catenin or TAZ has been demonstrated to
correlate with poor prognosis of a variety of malignancies,
however, the correlation of TAZ and β-catenin expression
in AEG and the relevance of their co-expression within
clinical parameters still remain unclear. Moreover,
the relationship between β-catenin and TAZ remains
controversial.
In this study, expression of TAZ and β-catenin was ex-
amined using immunohistochemistry on 135 AEG sam-
ples, compared with normal tissues and dysplasia samples.
The correlation of TAZ and β-catenin expression and its
relevance to clinicopathologic parameters were explored.
Furthermore, the prognostic roles of TAZ and β-catenin
in AEG were evaluated using Kaplan-Meier and Cox re-
gression analysis. To the best of our knowledge, it is the
first instance of reporting the correlation of TAZ and
β-catenin expression and their clinical significance for
patients with AEG.
Methods
Patients and tissue samples
The samples were obtained upon receipt of informed
consent from patients undergoing surgical resection.
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Shandong University School of Medicine (Jinan, China).
Total samples comprised 135 cases of adenocarcinoma, 37
cases of normal mucosa tissues and 41 cases of dysplasia
specimens which were located in EGJ. The cases were ob-
tained from the archives of the department of Pathology
at Qilu Hospital, Shandong University and collected from
patients who underwent surgery between January 2006
and December 2007. The diagnosis was confirmed histo-
logically in all cases, based mainly on examination of sec-
tions stained with H&E. Before surgery, no patients had
received drug intervention and preoperative chemother-
apy. Pathological characteristics were obtained from the
medical records and the original pathology reports, in-
cluding age, gender, tumour differentiation, tumour size,
lymph node status and invasion of serosa. AEG cases were
staged by TNM classification according to the standard
for oesophagogastric junction tumours of American Joint
Committee on Cancer (AJCC). Curative resection proced-
ure was performed in all AEG patients and the resection
boundaries were negative both in intraoperative and rou-
tine pathological diagnosis. The AEG patients were
followed up by phone call. The total period of follow-up
was 1–81 months (median was 35 months). The endpoint
of this study was overall survival which is defined as the
period lapsing from the date of initial biopsy until death
or last follow. By October 2013, 89 patients were reached
the end events.
Immunohistochemical stains
Immunohistochemical stains were performed on
formalin-fixed, paraffin-embedded specimens with the
PV-9000 2-step plus poly-HRP anti-mouse/rabbit IgG
detection system (ZSGB-Bio, Beijing, China) according
to the manufacturer’s instructions. Briefly, 4 μms e c -
tions were cut and placed on glass slides, then dewaxed
in xylene and rehydrated through graded alcohol. All
the slides were boiled in EDTA antigen retrieval solu-
tion (pH 9.0, ZSGB-Bio, Beijing, China) for 3 min to
retrieval the antigen. Thereafter, the sections were incu-
bated with 3% hydrogen peroxidase (reagent A) at room
temperature (RT) for 10 min to block endogenous perox-
idase activity. After rinsing in phosphate buffered saline
(PBS, PH 7.2), incubated with normal goat serum (ZSGB-
Bio, Beijing, China) to block any nonspecific reactions for
10 min at RT. Shook off excess goat serum, and then incu-
bated the slides with primary antibodies overnight at 4˚C,
TAZ (bs-12367R, Bioss, Beijing, China) and β-catenin
(ZM-0442, ZSGB-Bio, Beijing, China) were diluted 1:100
and 1:200 in PBS. The sections were washed with PBS and
incubated with polymer helper (reagent B) for 20 min.
After rinsing in PBS, the sections were incubated with
polyperoxidase-anti-mouse/rabbit IgG (reagent C) for
30 min at room temperature and DAB (ZSGB-Bio, Beijing,
China) was visualized. After rinsing in water, the sections
were counterstained with hematoxylin, dehydrated, and
coverslipped.
Figure 1 Expression of TAZ and β-catenin in adenocarcinoma, dysplasia and normal mucosa samples of EGJ. (A) TAZ-negative in normal
mucosa. (B) TAZ-positive in dysplasia. (C) TAZ-positive in adenocarcinoma. (D) TAZ-negative in adenocarcinoma. (E) TAZ-positive in intestinal
metaplasia. (F) Nuclear β-catenin negative and normal expression of membranous β-catenin in normal mucosa. (G) β-catenin- positive in
dysplasia. (H) β-catenin- positive in adenocarcinoma. (I) Abnormal membranous expression of β-catenin in adenocarcinoma. (Original
magnification, ×400).
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Samples of AEG with high expression of TAZ and β-
catenin served as the positive control. PBS was used in-
stead of the primary antibodies as negative controls.
Evaluation of immunostaining
TAZ and β-catenin immunostaining signals were evalu-
ated independently by two pathologists in a blinded man-
ner. Brown nuclear staining for TAZ was considered
positive/abnormal. The staining intensity of positive
tumour cells was scored as 0 (no staining), 1 (weak stain-
ing), 2 (moderate staining) and 3 (strong staining). The
percentage of positively stained tumour cells was scored
with 5 scales: 0 (<10 %); 1 (10% to 25%); 2 (26% to 50%); 3
(51% to 75%); 4 (>75%). The final score was the product
of the intensity and the percentage. For statistical reasons,
a final staining score ≥5 was considered to be positive. Nu-
clear and membranous β-catenin signals were evaluated
independently. When more than 10% of cancer cells
showed strong nuclear staining, the tumour was judged to
exhibit positive/abnormal nuclear expression. In cases that
demonstrated either no immunoreactivity at the mem-
brane, or less than 10% of the tumour cells with positive
membranous staining, the specimen was considered to ab-
normal membranous expression [32]. The percentage of
positively stained cells was estimated in an average of 100
cells counted in more than 5 high-power fields (×400).
Statistical analysis
Kruskal-Wallis text was used to assess the difference of
TAZ or β-catenin expression in the three groups. The re-
lationship between TAZ or β-catenin expression and clini-
copathologic parameters were analyzed using Chi-square
test and T test. The correlation between TAZ and β-
catenin was analyzed using the spearman’sr a n kt e s t .T h e
survival curves were estimated by the Kaplan–Meier
method. Log-rank test was used to compare survival
curves. The HR and the 95% CI were evaluated for each
variable using the Cox univariate model. A multivariate
Cox proportional hazard model was also developed using
stepwise regression (forward selection) with predictive
variables that were significant in the univariate analyses. P
<0.05 was considered to be statistically significant. All
statistical analyses were carried out using SPSS software
(SPSS version 17.0 SPSS, Inc., Chicago, IL, USA).
Results
Expression of TAZ and β-catenin
As shown in Figure 1 and Table 1, a positive expression
of TAZ was observed in normal mucosa 16.2% (6/37),
dysplasia 70.7% (29/41), and AEG 40.7% (55/135) and
the difference was significant (H =23.922, P <0.001).
The expression of TAZ in dysplasia and AEG is higher
than that in normal mucosa (P <0.001, =0.008). And it is
worth reminding that the expression of TAZ in dysplasia
is higher than that in AEG (P =0.001).
The positive nuclear expression rates of β-catenin in nor-
mal mucosa, dysplasia and AEG were 18.9% (7/37), 41.5%
(17/41) and 51.1% (69/135) and there was statistical differ-
ence among these groups (H = 12.277, P= 0.002). The
expression of β-catenin in AEG and dysplasia were signifi-
cantly higher than in normal mucosa (P <0.001, =0.046)
while no significant difference between AEG and dysplasia
(P=0.276).
The abnormal membranous expression rates of β-
catenin in the normal mucosa, dysplasia and AEG were
27% (10/37), 29.3% (12/41) and 57% (77/135), respectively.
There was a significant statistical difference among the
groups (H=16.482, P<0.001). Abnormal membranous
expression of β-catenin in AEG was significantly higher
than that in normal mucosa tissues and dysplasia (P=
0.001, 0.002), while no difference was found between nor-
mal mucosa tissues and dysplasia (P=0.843).
In AEG, interestingly, the statistical analysis revealed
that TAZ expression positively correlated with nuclear
β-catenin expression (r=0.298; confidence interval (CI)
95%, 0.136-0.462; P <0.001) (Table 2). In a separate ana-
lysis, abnormal membranous expression of β-catenin is
Table 1 Expression of TAZ and β-catenin proteins in different disease of EGJ
Total TAZ Nuclear β-catenin Membranous β-catenin
(n) Positive (%) Negative (%) Positive (%) Negative (%) Abnormal (%) Normal (%)
Normal mucosa 37 6(16.2) 31(83.8) 7(18.9) 30(81.1) 10(27) 27(73)
Dysplasia 41 29
*** (70.7) 12 (29.3) 17
* (41.5) 31(58.5) 12(29.3) 29(70.7)
AEG 135 55
**#(40.7) 80 (59.3) 69
*** (51.1) 66(48.9) 77
**#(57) 58(43)
Compared with Normal mucosa: *P < 0.05, **P < 0.01, ***P < 0.001; compared with Dysplasia:
#P < 0.01.
Table 2 Relationship between the expression of TAZ and
β-catenin in AEG
TAZ Membranous β-catenin Nuclear β-catenin
Normal Abnormal Negative Positive
Negative 41 39 49 31
Positive 17 38 17 38
r=0.202; P=0.019
* r=0.298; P< 0.001
*
*Statistically significant.
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Clinicopathologic
characteristics
TAZ P β-catenin (nuclear) P β-catenin (membranous) P TAZ & β-catenin (nuclear) P TAZ & β-catenin (membranous) P
Negative Positive Negative Positive Normal Abnormal Others Positive Others Positive
Gender
Male 64 46 0.593 52 58 0.431 45 65 0.312 79 31 0.99 64 46 0.842
Female 16 9 14 11 13 12 18 7 14 11
Age
<60 years old 26 22 0.371 13 35 0.001 21 27 0.891 31 17 0.163 22 26 0.037
≥60 years old 54 33 53 34 37 50 66 21 56 31
Invasion of serosa
Positive 21 38 0.001 21 38 0.006 18 41 0.010 31 28 0.001 25 34 0.001
Negative 59 17 45 31 40 36 66 10 53 23
lymphatic metastasis
Positive 34 42 0.001 30 46 0.013 27 49 0.048 43 33 0.001 37 39 0.015
Negative 46 13 36 23 31 28 54 5 41 18
Differentiation
Well-differentiated 51 22 0.007 43 30 0.012 47 26 0.001 59 14 0.012 57 16 0.001
Poorly differentiated 29 33 23 39 11 51 38 24 21 41
TNM stage
Stage 0 I II 55 24 0.004 43 36 0.126 39 40 0.074 65 14 0.001 65 32 0.001
Stage III IV 25 31 23 33 19 37 32 24 14 24
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5also correlated with expression of TAZ (r=0.202; CI
95%, 0.041-0.357; P =0.019).
Association of TAZ and β-catenin expression with clinico-
pathological characteristics
As shown in Table 3, the abnormal expression of TAZ,
nuclear β-catenin, membranous β-catenin, TAZ & nuclear
β-catenin and TAZ & membranous β-catenin were mark-
edly correlated with lymph node metastasis, invasion of
serosa and tumour differentiation (P<0.05, respectively).
In addition, the abnormal expression of nuclear β-catenin
and TAZ & membranous β-catenin were positively corre-
lated with age (P<0.001, =0.037). The abnormal expres-
sion of TAZ, membranous β-catenin, TAZ & nuclear
Figure 2 Kaplan–Meier analysis of overall survival rates in 135 AEG patients. β-catenin N, nuclear expression of β-catenin. β-catenin M,
membranous expression of β-catenin.
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edly correlated withTNM stages. There was no significant
association of TAZ or β-catenin expression with other
clinicopathological features mentioned in the table.
No significant correlations were found between ex-
pression of TAZ or β-catenin and tumour size. The
tumour size of TAZ positive cases was 4.74± 1.872
centimeter, the negative one was 5.03 ±1.923 centimeter,
P =0.392. The tumour sizes of nuclear β-catenin positive
was 4.92± 2.019 centimeter and the negative one was
4.79 ±1.686 centimeter, P =0.685. The tumour sizes of
abnormal expression membranous β-catenin was 4.89 ±
1.758 centimeter and the normal one was 4.83± 2.059
centimeter, P =0.863.
Association of TAZ and β-catenin expression with OS
When the AEG cases were analyzed by Kaplan–Meier
curves (Figure 2), we observed that the abnormal expres-
sion of TAZ, β-catenin (nuclear and membranous), nu-
clear β-catenin, membranous β-catenin, TAZ & nuclear
β-catenin and TAZ & membranous β-catenin signifi-
cantly affected overall survival rate of AEG patients (P <
0.05 for all). Patients with abnormal expression tumour
exhibited a shorter OS than those with normal one.
Moreover, patients with both TAZ and β-catenin (nu-
clear and membranous) abnormal expression exhibited
the worst survival (mean of 21.2 ±3.0 months and me-
dian of 19 months). On the contrary, patients with both
normal expression demonstrated the best overall survival
(mean of 63.4 ±5.2 months and median of 78 months,
P <0.001, Figure 3). As summarized in Table 4, the Cox
univariate model highlighted that abnormal expression
of TAZ, nuclear β-catenin, membranous β-catenin, TAZ
& nuclear β-catenin, TAZ & membranous β-catenin,
TAZ & β-catenin (nuclear and membranous) tumour
differentiation and nodal status significantly impact
overall survival time (P <0.05 for all). More importantly,
multivariate analysis revealed that tumour differentiation
(Hazard rate (HR) 1.870, CI 95%, 1.216-2.877, P =0.004),
TAZ expression (HR 1.879, CI 95%, 1.079-3.218, P =
0.022) and abnormal expression of TAZ & β-catenin
(nuclear and membranous) (HR 1.899, CI 95%, 1.053-
3.423, P =0.033) were independent negative prognostic
variables influencing OS.
Discussion
AEG includes adenocarcinomas of distal esophageal, car-
dia and proximal gastric and has been regarded as a separ-
ate entity because it appears to have distinct features.
Proximal gastric cancer, which is similar with distal
esophageal adenocarcinoma, is very different from distal
gastric cancer on patient’s age, gender, incidence, tumour
biological behaviors and clinicopathological features [33].
Lower thoracic esophageal carcinoma is more likely to
have lymph node metastasis, fast proliferation and poor
prognosis than the upper or middle one. So the concept
of AEG was put forward as a special entity. The incidence
of AEG is going higher than that of distal stomach cancer
[34]. The possible causes of AEG and gastric cancer are
different. Notably, it has been demonstrated that H. pylori
infection is one of the clear risk factors to gastric cancer,
while some research suggests that negative H. pylori status
correlates with a poor prognosis with AEG [35,36]. Gastric
cancers located in the distal stomach are associated with
better prognosis than those located in the proximal region
[37]. Differences in sex distinction and mean age were
found between AEG and the distal gastric cancer [38]. In
our study, the ratio of man to woman was 4.4 to 1, and
the average age was 62.6 years old, and patients of 60 years
old and above were accounted for 64.4 percent of AEG
patients, which were consistent with previous studies. The
rate of lymph node metastasis was 56.3%, and associated
with over expression of TAZ or β-catenin. Some earlier re-
searches produced similar findings: β-catenin was over
expressed in metastatic sentinel lymph node, and strongly
associated with liver metastasis [39]. The percentage of
well differentiated carcinoma in AEG (49.5%) was higher
than that in other malignant tumours [40].
The accumulated evidence from basic and clinical re-
searches indicates that both TAZ and β-catenin were
correlated with tumour invasion, metastasis, and poor
prognosis in human cancers [21,26,27,41,42]. However,
the regulation of TAZ upon β-catenin expression and
the relevance of their expression to clinical pathological
Figure 3 Kaplan–Meier analysis of AEG patients with abnormal
expression of TAZ & β-catenin (nuclear and membranous).
β-catenin N, nuclear expression of β-catenin. β-catenin M,
membranous expression of β-catenin.
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examined the expression of TAZ and β-catenin in 135
AEG specimens using immunohistochemistry stain, and
compared with expressions in normal mucosa and dys-
plasia samples. To our knowledge, it is the first time that
clinical evidence has been provided to indicate that TAZ
and β-catenin expression were positively correlated in
AEG.
TAZ is a WW domain containing transcriptional co-
activator that modulates cell differentiation and de-
velopment of multiple organs [7]. TAZ promotes cell
proliferation and epithelial-mesenchymal transition and
plays an important role in tumourigenesis [43]. Zhao
et al. reported that TAZ can promote cell growth in
breast partially through up-regulating KLF5 protein and
enhancing its activity and protecting it from WWP1-
mediated degradation [44]. There was also a report that
TAZ induces growth factor-independent proliferation
through activation of EGFR ligand amphiregulin [45].
Here we found that TAZ protein was strictly located in
the nucleus of AEG cells using IHC staining, and the
expression level of TAZ was significantly upregulated in
AEG and dysplasia than that in normal mucosa. More-
over, we also observed that the expression of TAZ was
positive in intestinal metaplasia of EGJ (Figure 1E). These
results suggest that TAZ upregulation is an early event in
the progression of AEG.
β-catenin plays an essential role in the regulation of
the E-cadherin-catenin cell adhesion complex as well as
in the Wnt signal pathway [20]. It has been reported that
β-catenin was significantly associated with the invasion
and metastasis of carcinomas of the esophagus, stomach,
colon, liver and melanomas [21,26,27,46]. In this study,
we evaluated nuclear and membranous β-catenin signals
respectively in immunohistochemical stain. Nuclear β-
catenin expression in three groups was similar with
TAZ, indicating that nuclear β-catenin accumulation
was involved in the carcinogenesis and tumour develop-
ment of AEG. While abnormal membranous expression
rate of β-catenin in AEG was higher than that in normal
mucosa and dysplasia, no difference between normal mu-
cosa and dysplasia. Furthermore, abnormal expression of
Table 4 Cox proportional hazard regression model analysis
Factors Univariate analysis Multivariate analysis
HR (95% CI) P-value HR (95% CI) P-value
TAZ
Positive vs. Negative 2.740 (1.791-4.192) <0.001
* 1.879 (1.097-3.218) 0.022
*
β-catenin (nuclear)
Positive vs. Negative 1.572 (1.028-2.402) 0.037
*
β-catenin (membranous)
Abnormal vs. Normal 2.153 (1.377-3.367) <0.001
*
TAZ & β-catenin (nuclear)
Positive vs. All others 2.482 (1.606-3.837) <0.001
*
TAZ & β-catenin (membranous)
Abnormal vs. All others 3.458 (1.732-6.908) <0.001
*
TAZ & β-catenin (nuclear and membranous)
Abnormal vs. All others 3.330 (2.082-5.328) <0.001
* 1.899 (1.053-3.423) 0.033
*
Tumor size (diameter)
≥ 3 cm vs. <3 cm 1.490 (0.886-2.506) 0.132
Lymph node status
Positive vs. Negative 1.548 (1.006-2.383) 0.047
*
Tumor differentiation
Poorly vs. Well-differentiated 2.165 (1.419-3.304) <0.001
* 1.870 (1.216-2.877) 0.004
*
Age (years)
≥ 60 vs. < 60 1.216 (0.782-1.890) 0.386
Gender
Male vs. Female 1.687 (0.918-3.102) 0.092
Invation of serosa
Positive vs. Negative 1.355 (0.893-2.057) 0.154
*Statistically significant.
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matastisis and invasion of serosa. We can infer that the
decreased expression of membranous β-catenin may
occur in later stage of AEG and associated with invasion
and metastasis.
In our study, the abnormal expression of TAZ, nuclear
β-catenin, membranous β-catenin, TAZ & nuclear β-
catenin and TAZ & membranous β-catenin were posi-
tively correlated with lymph node metastasis, invasion of
serosa and tumour differentiation which are crucial
histological features associated with poor prognosis, and
these findings were consistent with previous results. Be-
cause TNM classification is closely related to lymph
node status, tumour invasion and metastasis, the abnor-
mal expression of TAZ, membranous β-catenin, TAZ &
nuclear β-catenin and TAZ & membranous β-catenin
were also markedly correlated with TNM stages. We be-
lieve that the abnormal TAZ or β-catenin expression in
tumour cells promotes tumour cell EMT and, therefore,
facilitates tumour cell migration and metastasis into the
lymphatic vessels.
In this study over expression of TAZ and nuclear ex-
pression of β-catenin were positively correlated, which
was consistent with the previous findings [29-31]. We
can infer that except for acting as a transcription coacti-
vator, TAZ may play a key role in suppressing the deg-
radation of β-catenin and promoting β-catenin to enter
nuclear region. We also found that the expression of
TAZ was positively associated with decreased membran-
ous expression of β-catenin. However, the molecular
mechanism underlying this expression pattern and its
clinical importance need future investigation. One possible
mechanism is TAZ affects cadherin-mediated cell-cell
adhesion system by regulating membranous expression of
β-catenin.
Previously reported that colorectal cancer patients
with higher TAZ expression showed a trend of shorter
survival times [42]. Consistently, in our study the
Kaplan–Meier survival analysis revealed that patients
with abnormal expression of TAZ or β-catenin (nuclear
or membranous) expression showed worse OS than
those with normal TAZ or β-catenin expression. Further
still, patients with abnormal expression of both TAZ and
β-catenin (nuclear and membranous) exhibited the worst
overall survival. On the contrary, patients with both nor-
mal results demonstrated the best survival. These results
indicate that combining TAZ and β-catenin predicts
worse survival and may serve as the key molecular prog-
nostic indicator for AEG patient survival.
Consistent with previous reports, our Cox multivariate
analysis demonstrated that high TAZ expression levels
and combined abnormal expression of TAZ & β-catenin
(nuclear and membranous) were independent negative
prognostic factors together with tumour differentiation.
The result strongly suggests that TAZ and β-catenin
may serve as disease prognosis indicators for AEG
patient survival. Moreover, the regulation of TAZ on
β-catenin expression provides a new molecular me-
chanism underlying TAZ promoted AEG progression and
metastasis and may indeed suggest a feasible therapeutic
strategy to inhibit AEG metastasis by targeting TAZ and
β-catenin expressions.
Conclusions
In conclusion, our research demonstrated that over ex-
pression of TAZ was associated with abnormal expres-
sion of β-catenin in AEG. We also provided convincing
evidence that abnormal expression of TAZ or β-catenin
was correlated with the poor prognosis of patients with
AEG. Moreover, abnormal expression of TAZ and TAZ
& β-catenin (nuclear and membranous) could be inde-
pendent predictors of prognosis in AEG, so targeting
TAZ and β-catenin could prove to be a promising thera-
peutic strategy for the treatment of AEG.
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